Stage 4 Breast Cancer and ADC — How Enhertu and Trodelvy Altered Survival Curves

Stage 4 Breast Cancer and ADC — How Enhertu and Trodelvy Altered Survival Curves

From HER2-Low Breast Cancer to Triple Negative Breast Cancer, looking at the current state of metastatic breast cancer treatment through Overall Survival and Progression-Free Survival data

Stage 4 Breast Cancer: The Survival Gap Across Subtypes

Metastatic breast cancer is a complex disease that cannot be summarized by a single survival curve. According to a regional tumor registry cohort analysis in Germany, the median Overall Survival (OS) for cohorts diagnosed between 1995 and 2000 was 31.6 months, which significantly extended to 48.4 months for the 2018–2022 cohort. However, even within the same analysis, clear disparities remain visible across molecular subtypes.

The most dramatic clinical shifts are observed within the HER2-positive population. An analysis of 5,376 patients newly diagnosed with metastatic HER2-positive breast cancer between 2010 and 2020 utilizing the US National Cancer Database (NCDB) revealed that the real-world median Overall Survival reached 55.95 months—surpassing four and a half years. Conversely, Triple Negative Breast Cancer historically lingered at a median survival of just 12 to 18 months prior to the ADC era, underscoring the massive prognosis gap that remained between subtypes.

The Evolution of Treatment: Pre-ADC vs. Post-ADC Architecture

During the Pre-ADC era, clinical management for Stage 4 Breast Cancer was strictly bifurcated based on receptor status:

• ■ Hormone Receptor-Positive (HR+): Endocrine therapy ± CDK4/6 inhibitors
• ■ HER2-Positive Breast Cancer: Antibody-based targeted therapies such as trastuzumab and pertuzumab
• ■ Triple Negative Breast Cancer: Cytotoxic chemotherapy remained virtually the only viable option

The primary challenge across all three therapeutic arms was the lack of effective salvaging options once initial targeted therapies failed. Furthermore, patients with HER2-Low Breast Cancer (accounting for nearly half of all breast cancer cases, characterized by low HER2 expression that did not meet traditional criteria for HER2-positive therapies) were categorically grouped as HER2-negative, locking them out of anti-HER2 targeted interventions entirely.

The Post-ADC era resolved these therapeutic blind spots simultaneously. First, it established HER2-Low as a newly targetable clinical classification, delivering potent anti-HER2 ADC options to nearly half of the broader breast cancer patient population. Second, by introducing TROP2 as a novel target, it successfully brought antibody-guided precision oncology to Triple Negative Breast Cancer.

Advanced ADC Profiles: Clinical Data of Enhertu and Trodelvy

■ Enhertu (trastuzumab deruxtecan) — Solidifying the HER2-Low Therapeutic Axis

Published in 2022, the landmark phase 3 DESTINY-Breast04 trial was the first to evaluate Enhertu against physician’s choice of chemotherapy in patients with HER2-low (IHC 1+ or IHC 2+/ISH-negative) metastatic breast cancer. Long-term follow-up data presented in 2023 (reflecting the updated survival follow-up metrics) showed that in the overall cohort, the median OS reached 22.9 months in the Enhertu arm compared to 16.8 months in the chemotherapy arm, demonstrating a 31% reduction in the risk of death (Hazard Ratio [HR] 0.69). Within the HR+ subgroup, the median OS mirrored this extension at 23.9 months versus 17.6 months. Median PFS was also significantly prolonged by 4.8 months compared to chemotherapy (reaching 16.4 months), successfully meeting both primary and key secondary endpoints.

This milestone represents a historic paradigm shift, validating HER2-low as a distinct, treatable molecular entity that alters treatment pathways for nearly 50% of all breast cancer patients. However, interstitial lung disease (ILD) remains a critical adverse event that requires rigorous clinical monitoring, consistent with other deruxtecan-based platforms.

■ Trodelvy (sacituzumab govitecan) — Doubling Survival Outcomes in Triple Negative Breast Cancer

Sacituzumab govitecan, a first-in-class TROP2-directed ADC, demonstrated exceptional clinical efficacy in the phase 3 ASCENT trial for patients with previously treated metastatic Triple Negative Breast Cancer. Trodelvy nearly doubled the median OS to 12.1 months compared to just 6.7 months in the chemotherapy control arm, while substantially improving the objective response rate (ORR) from 5% to 35%. Median PFS similarly expanded from 1.7 months to 5.6 months.

Expanding its indications into HR+/HER2- metastatic breast cancer, the phase 3 TROPiCS-02 trial demonstrated that Trodelvy achieved a 21% reduction in the risk of death, extending the median OS by 3.2 months compared to conventional chemotherapy. Advancing further into front-line paradigms, the phase 3 ASCENT-04/KEYNOTE-D19 trial evaluated Trodelvy in combination with pembrolizumab (Keytruda) versus standard chemotherapy plus pembrolizumab as a first-line treatment for PD-L1-positive metastatic TNBC. The combination achieved a landmark median PFS of 11.2 months versus 7.8 months in the control arm, cutting the risk of disease progression or death by 35%, with the definitive findings published in The New England Journal of Medicine (NEJM).

Cross-Trial Comparison Matrix: Overall Survival and Progression-Free Survival

The trajectory across these clinical metrics points to a clear trend: ADC monotherapy in later-line settings delivers established, robust extensions in both OS and PFS, while shifting ADC configurations combined with checkpoint inhibitors into front-line regimens yields exceptionally strong PFS signals early in treatment.

2030 Projections: Shifting Life Expectancy in Stage 4 Breast Cancer

• ① Expanding Beyond HER2-Low to HER2-Ultralow: Ongoing clinical trials aim to identify and map even lower levels of HER2 expression to maximize ADC eligibility. As a result, the population of patients historically classified as strictly “HER2-negative” is expected to contract significantly.
• ② Standardization of First-Line TNBC Interventions: As frontline regimens like the ASCENT-04/KEYNOTE-D19 ADC-immunotherapy combination become standard care, the median overall survival for the historically poor-prognosis TNBC cohort is projected to rise significantly.
• ③ Bridging the Inter-Subtype Survival Disparity: With the real-world median overall survival for HER2-positive cohorts already crossing the 55-month mark, the next critical milestone for ADCs is to systematically close the survival gap for the more aggressive TNBC and refractory HR+/HER2- subtypes.

Frequently Asked Questions Regarding Stage 4 Breast Cancer and ADCs